MX2007005478A - Formulaciones de derivados de [1,4]diazepino[6,7,1-ij]quinolina. - Google Patents

Formulaciones de derivados de [1,4]diazepino[6,7,1-ij]quinolina.

Info

Publication number
MX2007005478A
MX2007005478A MX2007005478A MX2007005478A MX2007005478A MX 2007005478 A MX2007005478 A MX 2007005478A MX 2007005478 A MX2007005478 A MX 2007005478A MX 2007005478 A MX2007005478 A MX 2007005478A MX 2007005478 A MX2007005478 A MX 2007005478A
Authority
MX
Mexico
Prior art keywords
diazepino
formulations
quinoline derivatives
quinoline
idecahydrocyclopenta
Prior art date
Application number
MX2007005478A
Other languages
English (en)
Inventor
Yanning Lin
Wendy A Dulin
Mannching Sherry Ku
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2007005478A publication Critical patent/MX2007005478A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

La presente invencion provee formulaciones de dosificacion solidas de derivados de [1,4]diazepino[6,7,1-ij]quinolina, y procedimientos para su fabricacion; en algunas modalidades particulares, la presente invencion provee formulaciones novedosas del agente antipsicotico y antiobesidad clorhidrato de (9aR, 12aS)-4,5,6,7,9,9a,10,11,12,12a-decahidrociclopenta[c][1,4] diazepino[6,7,1-ij]quinolina, es decir, clorhidrato del compuesto A.
MX2007005478A 2004-11-05 2005-11-04 Formulaciones de derivados de [1,4]diazepino[6,7,1-ij]quinolina. MX2007005478A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62528004P 2004-11-05 2004-11-05
PCT/US2005/040290 WO2006052887A1 (en) 2004-11-05 2005-11-04 Formulations of [1,4]diazepino[6,7,1-ij]quinoline derivatives

Publications (1)

Publication Number Publication Date
MX2007005478A true MX2007005478A (es) 2007-05-24

Family

ID=35841773

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005478A MX2007005478A (es) 2004-11-05 2005-11-04 Formulaciones de derivados de [1,4]diazepino[6,7,1-ij]quinolina.

Country Status (19)

Country Link
US (1) US20060110451A1 (es)
EP (1) EP1807088A1 (es)
JP (1) JP2008519057A (es)
KR (1) KR20070084010A (es)
CN (1) CN101094675A (es)
AR (1) AR051946A1 (es)
AU (1) AU2005304758A1 (es)
BR (1) BRPI0517060A (es)
CA (1) CA2586124A1 (es)
GT (1) GT200500318A (es)
IL (1) IL182800A0 (es)
MX (1) MX2007005478A (es)
NO (1) NO20072169L (es)
PE (1) PE20060944A1 (es)
RU (1) RU2007114079A (es)
SV (1) SV2006002293A (es)
TW (1) TW200630100A (es)
WO (1) WO2006052887A1 (es)
ZA (1) ZA200703623B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
AU2007231011A1 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
CA2644656A1 (en) * 2006-03-24 2007-10-04 Wyeth Treatment of pain
AU2007229491A1 (en) * 2006-03-24 2007-10-04 Wyeth Methods for treating cognitive and other disorders
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
WO2009063992A1 (ja) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
CA2962959C (en) * 2014-10-08 2023-04-04 Synthetic Biologics, Inc. Beta-lactamase formulations and uses thereof
US10945974B2 (en) 2015-06-01 2021-03-16 Xeno Biosciences Inc. Methods and compositions to modulate the gut microbiota and to manage weight
CN105920017B (zh) * 2016-06-08 2018-06-05 广州嘉德乐生化科技有限公司 一种治疗单纯性肥胖症的药物组合物及其用途
CA3045011A1 (en) * 2016-11-30 2018-06-07 Xeno Biosciences Inc. Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
CN111743976A (zh) * 2020-07-03 2020-10-09 广西医科大学 一种二氧化硅气凝胶在制备治疗骨关节炎药物中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3158619A (en) * 1962-06-14 1964-11-24 Searle & Co Certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3235564A (en) * 1964-03-27 1966-02-15 Searle & Co Intermediates to certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3335134A (en) * 1964-04-02 1967-08-08 Sandoz Ag Certain 3, 4-dihydrofluoreno[1, 9a, 9-e, f]1, 4-diazepin-3(2h)-ones
US3296252A (en) * 1964-04-02 1967-01-03 Sandoz Ag Tetracyclic diazepinone compounds
GB1120461A (en) * 1964-07-06 1968-07-17 Manuf Prod Pharma Derivatives of fluoreno-[1,9-ef]1,4-diazepine-1-oxide
US3417101A (en) * 1964-11-09 1968-12-17 American Home Prod Fused ring compounds
US3329676A (en) * 1964-11-09 1967-07-04 American Home Prod Fused 1, 4-diazepine ring systems
US3714149A (en) * 1969-11-03 1973-01-30 Upjohn Co Pyridobenzodiazepinones
US3914250A (en) * 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
US4880814A (en) * 1987-11-13 1989-11-14 Abbott Laboratories 7-cycloalkyl naphthyridines
GB8812636D0 (en) * 1988-05-27 1988-06-29 Glaxo Group Ltd Chemical compounds
JPH02180885A (ja) * 1988-09-01 1990-07-13 Glaxo Group Ltd ラクタム誘導体
CA2195697A1 (en) * 1996-02-02 1997-08-03 Masahumi Kitano Novel substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof
US6380166B1 (en) * 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
US6761904B2 (en) * 2000-03-31 2004-07-13 Nycomed Austria Gmbh Pharmaceutical kit comprising midodrine as active drug substance
AR031199A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
US7141563B2 (en) * 2000-11-03 2006-11-28 Wyeth Process for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b] [1, 4]diazepino[6, 7, 1-hi] indole derivatives
AR031198A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de ciclopenta(b)diazepino(6,7,1)indol
AR031200A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
US6916922B2 (en) * 2000-11-03 2005-07-12 Wyeth Process for the preparation of 1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta [B] [1,4] diazepino- [6,7,1-hi] indole derivatives
AR031201A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp /1,4/diazepino/6,7,1-jk/carbazoles y derivados
AR031202A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
AR031196A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de ciclopenta (b) (1,4)-diazepino (6,7,1-hi) indoles y derivados
KR20030070073A (ko) * 2000-12-20 2003-08-27 브리스톨-마이어스스퀴브컴파니 세로토닌 효능제 및 길항제로서의 치환된 피리도인돌
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
BR0211559A (pt) * 2001-08-06 2004-07-13 Upjohn Co Compostos, composições de ligantes tetracìclicos terapeuticamente úteis e seus usos
TW200307540A (en) * 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TWI312781B (en) * 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) * 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
WO2004056324A2 (en) * 2002-12-19 2004-07-08 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
AU2004207578B2 (en) * 2003-01-28 2007-06-28 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
AU2007229491A1 (en) * 2006-03-24 2007-10-04 Wyeth Methods for treating cognitive and other disorders

Also Published As

Publication number Publication date
AR051946A1 (es) 2007-02-21
US20060110451A1 (en) 2006-05-25
GT200500318A (es) 2006-06-13
AU2005304758A1 (en) 2006-05-18
NO20072169L (no) 2007-07-24
RU2007114079A (ru) 2008-12-10
SV2006002293A (es) 2006-10-13
JP2008519057A (ja) 2008-06-05
KR20070084010A (ko) 2007-08-24
ZA200703623B (en) 2009-10-28
CA2586124A1 (en) 2006-05-18
TW200630100A (en) 2006-09-01
IL182800A0 (en) 2007-09-20
BRPI0517060A (pt) 2008-09-30
EP1807088A1 (en) 2007-07-18
CN101094675A (zh) 2007-12-26
PE20060944A1 (es) 2006-10-27
WO2006052887A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
MX2007005478A (es) Formulaciones de derivados de [1,4]diazepino[6,7,1-ij]quinolina.
HK1069388A1 (en) (1,4)diazepino(6,7,1-ij)quinoline derivatives as anti psychotic and antiobesity agents
UA93043C2 (ru) ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ ДЛЯ ПОЛУЧЕНИЯ ТРАНС-5-ХЛОР-2-МЕТИЛ-2,3,3А,12В-ТЕТРАГИДРО-1Н-ДИБЕНЗ[2,3:6,7]ОКСЕПИНО[4,5-с]ПИРОЛА
IL210823A (en) N - (alkyl-imidazo [5,1-a] pyridine-3-yl) -carboxamides, their history and their pharmaceutical preparations
WO2002044183A3 (en) Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
WO2006068826A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2003095455A3 (en) Substituted pyrazolopyrimidines
HUP0500163A3 (en) Pyrazolo [5,1-b]quinazoline derivatives and pharmaceutical compositions thereof as inhibitors of impdh enzyme
WO2006071862A3 (en) Polymorphs of 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate
IL190510A (en) Derivatives of pyrzolo [a-1,5] pyrimidine-7-illamine supported by the halogen in position 6 and (1 or 2) of methylpyrzole-4-ram in position 3, and pharmaceutical preparations containing them
WO2005049581A8 (en) Pyridazin-3 (2h) -one derivatives and their use as pde4 inhibitors
TNSN08059A1 (en) Novel crystalline form of a pyridazino [4,5-b] indole derivative
DK1497294T3 (da) 1,2,3,4,7,8-Hexahydro-6H[1,4]diazepino[6,7,1-ij]guinolinderivater som antipsykotiske midler og midler med adiposistas
WO2002048148A3 (en) Pyrazolopyridine derivatives
WO2003022209A3 (en) Crystalline forms of valacyclovir hydrochloride
WO2007031977A3 (en) Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors
SG144936A1 (en) 7-(4-substituted-3-cyclopropylaminomethyl-1- pyrrolidinyl)quinolonecarboxylic acid derivative
WO2006052886A8 (en) Metabolites of certain [1,4]diazepino[6,7,1-ij]quinoline derivatives and methods of preparation and use thereof
IL175724A0 (en) Tricyclic imidazopyridine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
AU2003266132A1 (en) Antidepressant azaheterocyclylmethyl derivatives of 4,5-dihydroimidazo(1,4,5-de)benzoxazine
HUP0105407A3 (en) Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
SI1560830T1 (sl) Derivati (6,7-dihidro-5H-imidazo(1,2-alfa)imidazol-3-sulfonilamino)-propionamida in njihova uporaba kot inhibitorji interakcije CAM in levkointegrinov
IL187441A0 (en) Derivatives of 6,7-dihydro-5h-imidazo[1,2-a] imidazole-3-sulfonic acid
WO2005007083A3 (en) Chemical compounds
AU2003240742A1 (en) 4,5-dihydro-imidazo (4,5,1-ij) quinolin-6-ones derivatives and their use as poly (adp-ribosyl) transferase (parp) inhibitors